Sugi Predict

Sugi Predict / Compounds / SCHEMBL873280

SCHEMBL873280

SCHEMBL873280

CC(C)(C)OC(=O)N1C[C@@H](O)C[C@@H]1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.59
▸ CYP1A2 P05177 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ CHRM2 P08172 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.43
▸ NR1H2 P55055 1/20 0.40
▸ HTRA1 Q92743 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MME P08473 1/20 0.37
▸ BTK Q06187 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ HSD11B1 P28845 1/20 0.35
▸ RIPK1 Q13546 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5200883 1.00 ATM (0.59) ATMCYP1A2POLBCYP3A4CYP2C19
SCHEMBL764093 1.00 ATM (0.59) ATMCYP1A2POLBCYP3A4CYP2C19
SCHEMBL242328 1.00 ATM (0.59) ATMCYP1A2POLBCYP3A4CYP2C19
SCHEMBL55610 1.00 ATM (0.59) ATMCYP1A2POLBCYP3A4CYP2C19
SCHEMBL116439 1.00 ATM (0.59) ATMCYP1A2POLBCYP3A4CYP2C19
SCHEMBL55611 1.00 ATM (0.59) ATMCYP1A2POLBCYP3A4CYP2C19
SCHEMBL193111 1.00 ATM (0.59) ATMCYP1A2POLBCYP3A4CYP2C19
SCHEMBL312687 1.00 ATM (0.59) ATMCYP1A2POLBCYP3A4CYP2C19
SCHEMBL4275881 0.98 ATM (0.57) ATMCYP1A2POLBCYP3A4CYP2C19
Ammonia Solution, Strong SCHEMBL29062671 0.98 ATM (0.57) ATMCYP1A2POLBCYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114797984-B Heterogeneous chiral bifunctional catalyst and preparation method and application thereof 东南大学 2023-08-25 — — CN claimed
CN-116396201-A Preparation method of (2R, 4R) -4-fluoropyrrolidine-2-carboxylic acid 南京优氟医药科技有限公司 2023-07-07 — — CN claimed
CN-114797984-A Heterogeneous chiral dual-function catalyst and preparation method and application thereof 东南大学 2022-07-29 — — CN claimed
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-14 — — US disclosed
EP-4731216-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2026-04-29 — — EP disclosed
EP-4695236-A1 SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2026-02-18 — — EP disclosed
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2026-01-01 — — US disclosed
WO-2025235389-A1 P53 MODULATORS NESTED THERAPEUTICS, INC. (US) 2025-11-13 — — WO disclosed
US-20250340548-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORP (US) 2025-11-06 — — US disclosed
US-12448389-B2 BRM targeting compounds and associated methods of use PRELUDE THERAPEUTICS INCORPORATED (US) 2025-10-21 — — US disclosed
WO-2001074769-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-10-11 — — WO disclosed
WO-2001072705-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-10-04 — — WO disclosed
EP-0618810-B1 BRADYKININ ANTAGONIST PEPTIDES SCIOS NOVA INC (US) 2001-07-04 — — EP disclosed
US-5385889-A Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist SCIOS NOVA INC. (US) 1995-01-31 — — US disclosed
CN-1027262-C Benzazepine and benzothiazepine derivatives E R SQUID & SONS INC (US) 1995-01-04 — — CN disclosed
EP-0618810-A4 BRADYKININ ANTAGONIST PEPTIDES. SCIOS NOVA INC (US) 1994-12-07 — — EP disclosed
EP-0618810-A1 BRADYKININ ANTAGONIST PEPTIDES SCIOS NOVA INC. (US) 1994-10-12 — — EP disclosed
WO-1992018156-A1 BRADYKININ ANTAGONIST PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 — — WO disclosed
CN-1039585-A BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES SQUIBB & SONS INC (US) 1990-02-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340548-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS ATM 1498/4885CYP1A2 4759/4885POLB 912/4885
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use GIPR, MC2R, GRPR ATM 4742/4885CYP1A2 1782/4885POLB 2709/4885
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME DDX21, PHAX, RBX1 ATM 4453/4885CYP1A2 4720/4885POLB 2834/4885
US-12448389-B2 BRM targeting compounds and associated methods of use ADRM1, BRDT, RBX1 ATM 2137/4885CYP1A2 4625/4885POLB 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.